Table 2.
Subgroup analysis of the prognostic value of NLR.
| Survival analysis | No. of studies | I2 (%) | HR (95% CI) | P |
|---|---|---|---|---|
| OS | ||||
| Total | 10 | 65% | 2.08 (1.60–2.69) | P < 0.00001 |
| Treatment | ||||
| Surgery | 6* | 14% | 1.97 (1.56–2.48) | P < 0.00001 |
| Mixed | 5 | 82% | 1.98 (1.27–3.08) | P = 0.002 |
| Stage | ||||
| Non-metastatic | 3† | 33% | 1.77 (1.34–2.33) | P < 0.0001 |
| Metastatic | 2 | 0% | 2.06 (1.45–2.92) | P < 0.0001 |
| Mixed | 6 | 80% | 2.33 (1.45–3.75) | P = 0.0005 |
| Ethnicity | ||||
| Asian | 5 | 59% | 1.72 (1.29–2.31) | P = 0.0003 |
| Latinos | 2 | 0% | 2.34 (1.84–2.98) | P < 0.00001 |
| Caucasian | 3 | 0% | 2.60 (1.66–4.06) | P < 0.0001 |
| DSS | ||||
| Total | 5 | 0% | 1.46 (1.21–1.77) | P < 0.0001 |
| Treatment | ||||
| Surgery | 4 | 0% | 1.38 (1.11–1.71) | P = 0.004 |
| Mixed | 1 | NA | 1.80 (1.20–2.70) | P = 0.004 |
| Stage | ||||
| Non-metastatic | 3 | 0% | 1.78 (1.29–2.46) | P = 0.0005 |
| Mixed | 2 | 45% | 1.32 (1.04–1.67) | P = 0.02 |
| Ethnicity | ||||
| Asian | 2 | 0% | 1.26 (1.00–1.60) | P = 0.05 |
| Caucasian | 3 | 0% | 1.92 (1.39–2.66) | P < 0.0001 |
| DFS | ||||
| Total | 6 | 0% | 1.72 (1.43–2.08) | P < 0.00001 |
| Treatment | ||||
| Surgery | 4 | 0% | 1.76 (1.42–2.18) | P < 0.00001 |
| Mixed | 2 | 7% | 1.62 (1.11–2.36) | P = 0.01 |
| Stage | ||||
| Non-metastatic | 3 | 0% | 1.71 (1.37–2.13) | P < 0.00001 |
| Metastatic | 1 | NA | 1.53 (1.03–2.26) | P = 0.03 |
| Mixed | 2 | 0% | 3.22 (1.43–7.27) | P = 0.005 |
| Ethnicity | ||||
| Asian | 4 | 0% | 1.67 (1.37–2.04) | P < 0.00001 |
| Caucasian | 2 | 0% | 2.14 (1.25–3.65) | P = 0.005 |
NA, not available.
*
Chan 2018's study has both surgery cohort and mixed treatment cohort.
†
Chan 2018's study has both metastatic group and non-metastatic group.